Home / Crime and Justice / Yukon Joins Opioid Lawsuit Against Big Pharma
Yukon Joins Opioid Lawsuit Against Big Pharma
15 Apr
Summary
- Yukon legislation enables participation in a class-action opioid lawsuit.
- The lawsuit targets opioid makers and sellers for deceptive marketing.
- New act simplifies Yukon's involvement, avoiding extensive documentation.
Yukon has passed legislation enabling its participation in a nationwide class-action lawsuit against opioid producers and sellers. This legal action, initiated by British Columbia in 2018, accuses the companies of using deceptive marketing to boost sales, consequently driving up addiction and overdose rates.
The Yukon's Opioid Damages and Health Care Costs Recovery Act, effective April 7, streamlines the territory's involvement. It permits the use of statistical, population-based evidence instead of requiring specific health care records or identifying individuals.
This initiative is comparable to a past lawsuit against tobacco companies, which resulted in substantial payments to provinces and territories. The trial for the opioid lawsuit is slated to begin in February 2028, though potential financial compensation for Yukon remains undetermined. The territory has been significantly impacted by the opioid crisis, with 127 deaths linked to opioids since 2016 and a declared substance use emergency in 2022.
